200
Views
0
CrossRef citations to date
0
Altmetric
Case Reports: Gynaecology

Anidulafungin treatment for fluconazole-resistant Candida albicans vaginitis with cross-resistance to azoles: a case report

ORCID Icon, , , , , & show all

References

  • Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved Standard – Third Edition. M27–A3. Vol. 28. Wayne, PA: Clinical and Laboratory Standards Institute.
  • Donders GG, Bellen G, Mendling W. 2010. Management of recurrent vulvo-vaginal candidosis as a chronic illness. Gynecologic and Obstetric Investigation 70:306–321.
  • Felix TC, de Brito Röder DVD, dos Santos Pedroso R. 2019. Alternative and complementary therapies for vulvovaginal candidiasis. Folia Microbiologica 64: 133–141.
  • Güzel AB, Döğen A, Aydın M, Serin A, Serin MS, Kalkancı A, et al. 2013. Genotyping reveals no link between Candida albicans genotype and vaginitis severity in Turkish women. Mycopathologia 175:287–294.
  • Karabay O, Bastug A, Ozturk R, Sencan I, Aksoy M, Simsek H, et al. 2018. Antibiotic Consumption, Resistance Data, and Prevention Strategies. Mediterraneon Journal of Infection, Microbes and Antimicrobials 7:35.
  • Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. 2012. Fluconazole-Resistant Candida albicans Vulvovaginitis. Obstetrics and Gynecology 120: 1407–1414.
  • Sobel JD. 2016. Recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology 214:15–21.
  • Sobel JD, Sobel R. 2018. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opinion on Pharmacotherapy 19:971–977.
  • van Schalkwyk J, Yudin MH, Yudin MH, Allen V, Bouchard C, Boucher M, et al. 2015. Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis. Journal of Obstetrics and Gynaecology Canada 37:266–274.
  • Workowski KA, Bolan GA; Centers for Disease Control and Prevention. 2015. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommendations and Reports 64:1–137.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.